Clinical Report: The Impact of Aberrant Lactate Dehydrogenase A on Immune Cell Anti-Tumor Responses
Overview
This review highlights the role of Lactate dehydrogenase A (LDHA) in modulating immune cell metabolism and anti-tumor responses, particularly in the context of immunotherapies such as CAR-T therapy and immune checkpoint inhibitors.
Background
Lactate dehydrogenase A (LDHA) is crucial in the metabolic reprogramming of malignant tumors, facilitating the Warburg effect and influencing tumor progression. Understanding LDHA's role in immune cells is essential, as it can significantly affect immune responses within the tumor microenvironment through mechanisms such as immune cell polarization and metabolic reprogramming.
Data Highlights
No numerical data available in the source material.
Key Findings
LDHA is overexpressed in various human malignancies, contributing to tumor progression and immune modulation.
LDHA influences the differentiation and functional status of tumor-infiltrating immune cells, affecting their pro-inflammatory or immunosuppressive phenotypes.
Metabolic reprogramming of immune cells by LDHA alters redox homeostasis and immune effector activation.
Combining LDHA inhibitors with immunotherapies like CAR-T therapy may enhance therapeutic efficacy.
Current clinical guidelines do not recommend LDHA testing, but LDH levels are used as prognostic indicators in cancer management.
Clinical Implications
Clinicians should consider the metabolic role of LDHA in immune cells when designing cancer therapies, as targeting LDHA may improve the effectiveness of existing immunotherapies and provide a novel strategy for enhancing anti-tumor immunity.
Conclusion
The review underscores the importance of LDHA in immune cell metabolism and its potential as a therapeutic target in cancer treatment. Further research is warranted to explore LDHA's role in enhancing immunotherapy outcomes, particularly in specific cancer types.
